Efficient antibacterial zinc oxide nano particle with bone targeting property as well as preparation method and application of efficient antibacterial zinc oxide nano particle

By grafting bone-targeting materials on the surface of zinc oxide nanoparticles, the efficient antibacterial zinc oxide nanoparticles with bone targeting are solved, and the problem of poor targeting of traditional antibacterial agents in orthopedic infections is achieved is achieved with high efficiency in bone infection sites Clean and reduce side effects.

CN118987253AActive Publication Date: 2024-11-22SICHUAN UNIV

Patent Information

Application Number
CN202411079156.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-22
Estimated Expiration
2044-08-07

AI Technical Summary

Technical Problem

The prior art is difficult to effectively target bone tissue for antibacterial treatment, especially in orthopedic infections such as osteomyelitis. Antibiotic resistance is serious, and traditional antibacterial agents are difficult to target the infected site, resulting in poor treatment effects and great side effects.

Method used

By modifying the surface of zinc oxide nanoparticles, bone-targeting materials such as aspartate hexapeptide are grafted to form highly efficient antibacterial zinc oxide nanoparticles with bone targeting, using their broad-spectrum antibacterial ability and through targeting ability Directed to the site of bone infection.

Benefits of technology

It has achieved efficient cleaning of bacteria in the bone-infected site, reduced dosage, reduced side effects on healthy tissues, improved treatment effect, and has good clinical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987253A_ABST
    Figure CN118987253A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biomedical materials, and discloses a bone-targeting efficient antibacterial zinc oxide nanoparticle, which comprises a zinc oxide nanoparticle with an active site and a bone-targeting material grafted on the surface of the zinc oxide nanoparticle through the active site. The active site is amino; the bone targeting material is one of aspartic acid oligopeptide and glutamic acid oligopeptide. The invention further discloses a preparation method and application of the efficient antibacterial zinc oxide nanoparticles with the bone targeting property. The efficient antibacterial zinc oxide nanoparticles with the bone targeting property, provided by the invention, can be oriented to a bone infection part through the targeting capability of a bone targeting material on hydroxyapatite in bone tissues, and then the broad-spectrum antibacterial capability of the zinc oxide nanoparticles is exerted to kill bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedical materials, and specifically relates to a high-efficiency antibacterial zinc oxide nanoparticle with bone targeting, and a preparation method and application thereof. Background Art

[0002] Bacterial infection in bone tissue is an acute or chronic inflammation caused by microbial infection. Osteomyelitis is a typical representative of orthopedic infection. It is an inflammatory process caused by purulent microbial infection and is often accompanied by bone destruction. It is mostly caused by local spread of infection after trauma, orthopedic surgery or joint replacement. It can be limited to a certain part of the bone, or it can involve multiple parts such as the bone marrow, cortex, periosteum and surrounding soft tissue, which can cause severe pain in bones and joints and bone degenerative changes.

[0003] The main pathogens of osteomyelitis cases are Gram-negative bacteria such as Pseudomonas aeruginosa (P.aeruginosa), Escherichia coli (E.coli), etc., and Gram-positive bacteria such as Staphylococcus aureus (S.aureus), Staphylococcus epidermidis, Enterococcus, Streptococcus, etc. Staphylococcus aureus is the most common pathogen in osteomyelitis, which can destroy bone tissue by inducing osteoblast apoptosis, activating osteoclast formation and secreting toxins. The conventional clinical treatment of osteomyelitis is long-term, high-dose antibiotic treatment combined with multiple surgical debridements. Since the first discovery of penicillin in 1928, antibiotics have been widely used in the field of antibacterial and effectively treat a variety of infectious diseases. However, the overuse of antibiotics has led to serious bacterial resistance to antibiotics. According to incomplete statistics, about 700,000 people die from drug-resistant bacterial infections every year worldwide. If they are not effectively treated, it is estimated that this number will reach 10 million per year by 2050. Therefore, it has become an urgent need to develop effective and safe antibacterial drugs to treat osteomyelitis.

[0004] Zinc oxide (ZnO) nanoparticles (NPs) have been shown to have strong antimicrobial effects and are made of metal ions that can be activated in biocides. They have low stability under high temperature / pressure and have good robustness compared to organic antimicrobials. ZnO NPs are able to change the composition of bacterial cell membranes, causing distortions, resulting in loss of intracellular materials, leading to bacterial cell death. ZnO NPs have a broad spectrum of antimicrobial capabilities, including Gram-negative and Gram-positive strains. They have attracted great interest due to their significant ability to inhibit bacterial growth and proliferation.

[0005] In recent years, significant progress has been made in the development and application of bone-targeted biomaterials. Nanocarrier drug delivery through targeted strategies is a promising approach that can provide more effective treatments for bone-related diseases, improve treatment efficacy, and reduce side effects. In bones, active targeted drugs utilize specific interactions with osteoids to improve the selective accumulation of targeted sites, thereby achieving the function of enhancing disease treatment and reducing side effects in healthy tissues. The developed bone-targeting groups are a class of small molecules with high affinity for bone tissue, such as bisphosphonate systems, oligopeptide systems, tetracycline drugs, and aptamer systems.

[0006] Therefore, how to combine ZnO nanoparticles with bone-targeted biomaterials to develop bone-targeted zinc oxide nanoparticles is the main technical problem to be solved by the present invention. Summary of the invention

[0007] The purpose of the present invention is to address the technical problems existing in the above-mentioned prior art and provide a bone-targeted, highly efficient, antibacterial zinc oxide nanoparticle and a preparation method thereof, so as to improve the targeted antibacterial ability of nano zinc oxide by modifying the surface of zinc oxide nanoparticles and grafting bone-targeting materials.

[0008] The present invention also provides the use of the above-mentioned bone-targeted high-efficiency antibacterial zinc oxide nanoparticles for preparing bone tissue therapeutic drugs.

[0009] In order to achieve the above object, the present invention adopts the following technical solutions to achieve it.

[0010] The invention provides a bone-targeted and highly effective antibacterial zinc oxide nanoparticle, comprising zinc oxide nanoparticles with active sites and bone-targeted materials grafted onto the surface of the zinc oxide nanoparticles via the active sites.

[0011] The above-mentioned bone-targeted high-efficiency antibacterial zinc oxide nanoparticles, the active site is an amino group; the bone-targeting material is one of aspartic acid oligopeptide, glutamic acid oligopeptide, etc. Preferably, the bone-targeting material is aspartic acid hexapeptide; there are multiple carboxyl groups on the aspartic acid hexapeptide group; the zinc oxide nanoparticles with active sites are combined with the terminal carboxyl group on the aspartic acid hexapeptide (Asp6) through an amide bond, which can ensure the stability of the combination of the two materials and retain the bone-targeting performance of the material.

[0012] The present invention also provides a method for preparing the above-mentioned bone-targeted high-efficiency antibacterial zinc oxide nanoparticles, which comprises the following steps:

[0013] (1) using a silane coupling agent to perform surface amino modification on zinc oxide nanoparticles to obtain surface-modified zinc oxide nanoparticles;

[0014] (2) Preparation of bone-targeted zinc oxide nanoparticles, specifically:

[0015] The surface-modified zinc oxide nanoparticles are added to a bone-targeting material buffer with a pH of 5-5.5, and the pH of the resulting reaction system is adjusted to 5.5-6.5, followed by stirring for 4-5 hours, and then filtered, washed, and dried to obtain bone-targeting high-efficiency antibacterial zinc oxide nanoparticles; the mass ratio of the surface-modified zinc oxide nanoparticles to the bone-targeting material is 10:1.

[0016] The purpose of the above step (1) is to modify the surface of zinc oxide nanoparticles and graft amino groups with high reactive sites. The silane coupling agent is one of γ-aminopropyltriethoxysilane (KH550), γ-methacryloxypropyltrimethoxysilane (KH570), etc. The surface modification of zinc oxide nanoparticles by the silane coupling agent consumes the hydroxyl groups on the surface of zinc oxide nanoparticles, effectively improving the situation that the nanoparticles are easy to agglomerate. At the same time, the surface of zinc oxide nanoparticles modified by the silane coupling agent is rich in amino groups with high reactive activity, which is conducive to the multifunctional modification of the nanoparticles.

[0017] In a specific implementation, step (1) includes the following sub-steps:

[0018] (11) adding a silane coupling agent to the uniformly dispersed zinc oxide nanoparticle dispersion and subjecting the mixture to ultrasonic treatment for 20-40 min; the silane coupling agent is 20%-22% of the mass of the zinc oxide nanoparticles;

[0019] (12) The dispersion after ultrasonic treatment is centrifuged multiple times, washed and dried to obtain surface-modified zinc oxide nanoparticles.

[0020] In the above step (11), the zinc oxide nanopowder is added to anhydrous ethanol and dispersed evenly by ultrasonication to obtain a zinc oxide nanoparticle dispersion with a concentration of 20 mg / mL. The ultrasonic dispersion time here is 15-20 min.

[0021] In the above step (12), the dispersion after ultrasonic treatment is first centrifuged to obtain a precipitate, and the obtained precipitate is then washed with anhydrous ethanol. The above centrifugation and washing operations are repeated at least three times, and the product of the last washing is then centrifuged. The product obtained by centrifugation is dried to obtain surface-modified zinc oxide nanoparticles. The centrifugation conditions are: speed 5000-8000 rpm, time 5-10 min. The drying conditions are: 50-80° C., 12-24 h.

[0022] In the above step (2), bone-targeted zinc oxide nanoparticles are grafted with bone-targeted materials on the surface of surface-modified zinc oxide nanoparticles to obtain bone-targeted zinc oxide nanoparticles, which is mainly achieved by surface grafting of bone-targeted materials. After the bone-targeted materials (preferably aspartic acid hexapeptide (Asp6)) with bone-targeting ability are grafted, the bone-targeted materials are directed to the bone infection site through the targeting ability of the bone-targeting materials to hydroxyapatite in the bone tissue, and then the broad-spectrum antibacterial ability of the nano zinc oxide particles is exerted to kill bacteria.

[0023] First, the bone targeting material is dissolved in the first buffer to obtain a bone targeting material buffer with a concentration of 0.5g / L, and the pH value of the bone targeting material buffer is adjusted to 5-5.5 by acid. The first buffer is a MES buffer containing EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) and NHS (NHS is N-hydroxysuccinimide); the mass ratio of EDC and NHS is 1:1; the volume ratio of the total mass of EDC and NHS to the MES buffer is 10mg-20mg:1mL. The acid is hydrochloric acid, and its concentration is 0.1M; the bone targeting material buffer after adding the acid is stirred at room temperature for 30-40min to mix evenly and fully activate the carboxyl group of the bone targeting material.

[0024] The surface-modified zinc oxide nanoparticles are then added to a bone-targeted material buffer, and the pH value of the resulting reaction system is adjusted to 5.5-6.5 using a second buffer. The second buffer is a commercially available PBS buffer, and its pH range is 7.2-7.4. After the resulting reaction system is stirred at room temperature, the precipitate is collected by centrifugal filtration, and the resulting precipitate is washed with ultrapure water and dried to obtain bone-targeted, highly efficient antibacterial zinc oxide nanoparticles. The drying conditions are: 50-60°C, 12-24h.

[0025] Unless otherwise specified, the above steps (1)-(2) are all carried out at room temperature.

[0026] The present invention also provides the use of the above-mentioned bone-targeted high-efficiency antibacterial zinc oxide nanoparticles in the preparation of bone tissue therapeutic drugs, mainly in the preparation of osteomyelitis therapeutic drugs.

[0027] Osteomyelitis caused by suppurative microbial infection is accompanied by an inflammatory reaction of bone destruction, which is mostly caused by local spread of infection after trauma, orthopedic surgery or joint replacement. It can be confined to a certain part of the bone, or it can involve multiple parts such as bone marrow, cortex, periosteum and surrounding soft tissue. After the pathogen invades the bone area, it releases proteolytic enzymes and free radicals, induces inflammation, destroys surrounding tissues, causes blood to flow to the infected area, and increases the chance of bone destruction. Hydroxyapatite (HA) is an important component of bone. Compared with traditional osteomyelitis treatment methods, the zinc oxide nanoparticles modified with aspartic acid hexapeptide (Asp6) provided by the present invention can target hydroxyapatite in bone tissue at the bacterial infection site; zinc oxide nanoparticles with surface binding to aspartic acid hexapeptide (Asp6) can play a broad-spectrum antibacterial effect at the infection site to kill bacteria. Compared with the treatment method of systemic administration of traditional antibiotics, the bone-targeted nano zinc oxide particles provided by the present application can achieve efficient cleaning of bacteria at the bone infection site while reducing the dosage, and have good application prospects for the treatment of osteomyelitis in the clinic.

[0028] Compared with the prior art, the present invention has the following beneficial effects:

[0029] 1) The bone-targeted and highly effective antibacterial zinc oxide nanoparticles provided by the present invention graft bone targeting materials onto the surface of zinc oxide nanoparticles, and can be directed to the bone infection site through the targeting ability of the bone targeting materials to hydroxyapatite in bone tissue, and then the broad-spectrum antibacterial ability of zinc oxide nanoparticles is exerted to kill bacteria;

[0030] 2) The present invention utilizes the zinc oxide nanoparticles with highly reactive sites on the surface after activation and modification to bind to the terminal carboxyl group on the aspartic acid hexapeptide (Asp6) through an amide bond. At the same time, the aspartic acid hexapeptide (Asp6) can also bind to the Ca in the mineralized tissue. 2+ The interaction produces a strong affinity, thereby forming a stable structure between zinc oxide nanoparticles and aspartic acid hexapeptide (Asp6), so that the prepared material has both bone targeting performance and broad-spectrum antibacterial ability. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 The preparation process of the bone-targeted and highly effective antibacterial zinc oxide nanoparticles ZnO-Asp6 in Example 1;

[0032] Figure 2 Schematic diagram of the preparation principle of the bone-targeted and highly effective antibacterial zinc oxide nanoparticles ZnO-Asp6 in Example 1;

[0033] Figure 3The surface modification scanning electron microscope morphology observation of ZnO nanoparticles prepared in Example; wherein, (a) is the zinc oxide nanoparticles before modification (magnified 10000 times), (b) is the zinc oxide nanoparticles after modification (magnified 10000 times), (c) is the zinc oxide nanoparticles after modification (magnified 4000 times);

[0034] Figure 4 FTIR curve of the successfully prepared nano zinc oxide powder with highly reactive sites on the surface;

[0035] Figure 5 The in vitro binding ability of the ZnO-Asp6 bone-targeted nanoparticles prepared in Example 1 to hydroxyapatite; wherein (a) is the binding of nanoparticles of different concentrations to hydroxyapatite within 24 hours, and (b) is a schematic diagram of the principle;

[0036] Figure 6 The antibacterial ability of ZnO-Asp6 bone-targeted nanoparticles prepared in Example 1; wherein (a) is parallel experimental group 1; and (b) is parallel experimental group 2. DETAILED DESCRIPTION

[0037] The following will clearly and completely describe the technical solutions of various embodiments of the present invention in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0038] Example 1

[0039] The zinc oxide nanoparticles used in this embodiment have a particle size of 20-200 nm; the silane coupling agent used is γ-aminopropyltriethoxysilane (KH550); and the bone targeting material used is aspartic acid hexapeptide (Asp6).

[0040] The preparation process of the bone-targeted and highly effective antibacterial zinc oxide nanoparticles ZnO-Asp6 provided in this embodiment is as follows: Figure 1 As shown, firstly, KH550 is used to activate the surface of zinc oxide. The specific reaction formula is shown in Figure 2 As shown, KH550 is grafted onto the surface of zinc oxide nanoparticles. On the one hand, it consumes the hydroxyl groups on the surface of zinc oxide nanoparticles, effectively improving the easy agglomeration of nanoparticles. On the other hand, the surface of zinc oxide nanoparticles is amino-modified. Then, based on the amidation reaction, aspartic acid hexapeptide Asp6 is grafted onto the surface of the modified zinc oxide nanoparticles through its carboxyl group to obtain a ZnO-Asp6 surface.

[0041] Specifically, this embodiment prepares bone-targeted, highly efficient antibacterial zinc oxide nanoparticles ZnO-Asp6 according to the following steps:

[0042] (1) using a silane coupling agent to perform surface amino modification on zinc oxide nanoparticles to obtain surface-modified zinc oxide nanoparticles; specifically comprising the following steps:

[0043] (11) 0.2 g of zinc oxide nanopowder was added to 10 mL of anhydrous ethanol and ultrasonicated for 15 min to disperse uniformly; then 38 μL of KH550 was added to the uniformly dispersed zinc oxide nanoparticle dispersion (the mass of KH550 was about 20% of the zinc oxide nanopowder), and ultrasonication was continued for 30 min;

[0044] (12) The dispersion after ultrasonic treatment was transferred to a 50 mL centrifuge tube and centrifuged at 5000 rpm for 5 min to retain the precipitate; then 40 mL of anhydrous ethanol was added for washing; the above centrifugation and washing operations were repeated three times, and the product of the last washing was centrifuged. The product obtained by centrifugation was placed in a vacuum oven at 60 ° C and dried for 24 h to obtain surface-modified zinc oxide nanoparticles.

[0045] (2) Preparation of bone-targeted zinc oxide nanoparticles, specifically:

[0046] 100 mg EDC and 100 mg NHS were dissolved in 10 mL MES buffer and mixed evenly to obtain the first buffer (EDC / NHS-MES buffer); 5 mg aspartic acid hexapeptide (Asp6) was dissolved in 10 mL of the first buffer to obtain an aspartic acid hexapeptide (Asp6) buffer with a concentration of 0.5 g / L, and the pH value of the aspartic acid hexapeptide (Asp6) buffer was adjusted to 5.5 by 0.1 M hydrochloric acid, and then stirred at room temperature for 30 min. 50 mg of surface-modified zinc oxide nanoparticles were added to the aspartic acid hexapeptide (Asp6) buffer, and the pH of the resulting reaction system was adjusted to 6.0 using PBS buffer, and then stirred at room temperature for 4 h. The resulting product was collected by centrifugal filtration and precipitated, and then washed with ultrapure water, and then placed in a vacuum oven at 60 ° C for 24 h to obtain bone-targeted, highly efficient antibacterial zinc oxide nanoparticles ZnO-Asp6.

[0047] Example 2

[0048] The zinc oxide nanoparticles used in this embodiment have a particle size of 20-200 nm; the silane coupling agent used is γ-methacryloxypropyltrimethoxysilane (KH570); and the bone targeting material used is aspartic acid hexapeptide (Asp6).

[0049] This example prepares bone-targeted, highly effective antibacterial zinc oxide nanoparticles ZnO-Asp6 according to the following steps:

[0050] (1) using a silane coupling agent to perform surface amino modification on zinc oxide nanoparticles to obtain surface-modified zinc oxide nanoparticles; specifically comprising the following steps:

[0051] (11) 0.2 g of zinc oxide nanopowder was added to 10 mL of anhydrous ethanol and ultrasonicated for 15 min to disperse uniformly; then 43 μL of KH570 was added to the uniformly dispersed zinc oxide nanoparticle dispersion (the mass of KH570 was about 22% of the zinc oxide nanopowder), and ultrasonication was continued for 20 min;

[0052] (12) The dispersion after ultrasonic treatment was transferred to a 50 mL centrifuge tube and centrifuged at 5000 rpm for 10 min to retain the precipitate; then 40 mL of anhydrous ethanol was added for washing; the above centrifugation and washing operations were repeated three times, and the product of the last washing was centrifuged. The product obtained by centrifugation was placed in a vacuum oven at 80 ° C and dried for 12 h to obtain surface-modified zinc oxide nanoparticles.

[0053] (2) Preparation of bone-targeted zinc oxide nanoparticles, specifically:

[0054] 50 mg EDC and 50 mg NHS were dissolved in 10 mL MES buffer and mixed evenly to obtain the first buffer (EDC / NHS-MES buffer); 5 mg Aspartic acid hexapeptide (Asp6) was dissolved in 10 mL of the first buffer to obtain an Aspartic acid hexapeptide (Asp6) buffer with a concentration of 0.5 g / L, and the pH value of the Aspartic acid hexapeptide (Asp6) buffer was adjusted to 5 by 0.1 M hydrochloric acid, and then stirred at room temperature for 30 min. 50 mg of surface-modified zinc oxide nanoparticles were added to the Aspartic acid hexapeptide (Asp6) buffer, and the pH of the resulting reaction system was adjusted to 5.5 using PBS buffer, and then stirred at room temperature for 4 h. The resulting product was collected by centrifugal filtration and precipitated, and then washed with ultrapure water, and then placed in a vacuum oven at 50 ° C for 24 h to obtain bone-targeted, highly efficient antibacterial zinc oxide nanoparticles ZnO-Asp6.

[0055] Example 3

[0056] The zinc oxide nanoparticles used in this embodiment have a particle size of 20-200 nm; the silane coupling agent used is γ-aminopropyltriethoxysilane (KH550); and the bone targeting material used is glutamic acid hexapeptide (Glu6).

[0057] This example prepares bone-targeted, highly effective antibacterial zinc oxide nanoparticles ZnO-Glu6 according to the following steps:

[0058] (1) using a silane coupling agent to perform surface amino modification on zinc oxide nanoparticles to obtain surface-modified zinc oxide nanoparticles; specifically comprising the following steps:

[0059] (11) 0.2 g of zinc oxide nanopowder was added to 10 mL of anhydrous ethanol and ultrasonicated for 20 min to disperse uniformly; then 38 μL of KH550 was added to the uniformly dispersed zinc oxide nanoparticle dispersion (the mass of KH550 was approximately 20% of the zinc oxide nanopowder), and ultrasonication was continued for 30 min;

[0060] (12) The dispersion after ultrasonic treatment was transferred to a 50 mL centrifuge tube and centrifuged at 8000 rpm for 5 min to retain the precipitate; then 35 mL of anhydrous ethanol was added for washing; the above centrifugation and washing operation was repeated three times, and the product of the last washing was centrifuged. The product obtained by centrifugation was placed in a vacuum oven at 50 ° C and dried for 24 h to obtain surface-modified zinc oxide nanoparticles.

[0061] (2) Preparation of bone-targeted zinc oxide nanoparticles, specifically:

[0062] 100 mg EDC and 100 mg NHS were dissolved in 10 mL MES buffer and mixed evenly to obtain the first buffer (EDC / NHS-MES buffer); 5 mg glutamic acid hexapeptide (Glu6) was dissolved in 10 mL of the first buffer to obtain a glutamic acid hexapeptide (Glu6) buffer with a concentration of 0.5 g / L, and the pH value of the glutamic acid hexapeptide (Glu6) buffer was adjusted to 5.5 by 0.1 M hydrochloric acid, and then stirred at room temperature for 40 min. 50 mg of surface-modified zinc oxide nanoparticles were added to the glutamic acid hexapeptide (Glu6) buffer, and the pH of the resulting reaction system was adjusted to 6.5 using PBS buffer, and then stirred at room temperature for 5 h. The resulting product was collected by centrifugal filtration and precipitated, and then washed with ultrapure water, and then placed in a vacuum oven at 60 ° C for 24 h to obtain bone-targeted, highly efficient antibacterial zinc oxide nanoparticles ZnO-Glu6.

[0063] (I) Structural characterization

[0064] The surface modified zinc oxide nanoparticles prepared in Example 1 were examined by scanning electron microscopy. Figure 3 Figure (a) shows the zinc oxide nanoparticles before modification, which are granular in shape, with a size between 20-200nm and obvious agglomeration; Figures (b) and (c) show the zinc oxide nanoparticles modified with KH550 silane coupling agent, showing that their agglomeration degree has been improved and the particle size has not changed significantly.

[0065] The surface modified zinc oxide nanoparticles prepared in Example 1 were subjected to infrared testing, and the results were as follows: Figure 4 As shown in the figure, the infrared spectrum of zinc oxide nanoparticles before modification is 500-600cm -1 There is a strong absorption peak at 3675-3131cm, corresponding to the bending vibration of the Zn-O bond in zinc oxide. -1 Peaks in the range (≈3411cm -1 ) is the stretching vibration of the -OH group. After modification with KH550 coupling agent, the vibration peak of Si-O is at ≈546cm- 1 The original location is 3411cm -1 The stretching vibration peak of the -OH group at 200 nm shifted to a lower wave number and became broader. This is due to the successful grafting of -NH2, indicating the successful modification of zinc oxide nanoparticles by KH550.

[0066] (II) Characterization of the specific binding ability of ZnO-Asp6 to hydroxyapatite powder

[0067] 1. Material preparation:

[0068] 1) Weigh 20 mg of 400-mesh sieved hydroxyapatite powder and disperse it in 200 mL of PBS buffer (commercially available, pH about 7.2-7.4), set the stirring rate to 500 rpm, and stir overnight for use.

[0069] 2) Prepare PBS dispersions of ZnO-Asp6 (prepared in Example 1) with different concentration gradients (0.056M, 0.112M, 0.224M, 0.336M) for later use.

[0070] 2. Experimental methods:

[0071] 900 μL of hydroxyapatite powder dispersion was mixed with 100 μL of PBS dispersion of ZnO-Asp6 of different concentrations and placed in a shaker at 37°C for 24 h.

[0072] After shaking for 24 hours, the mixed liquid was placed in a centrifuge and centrifuged at 10000rpm for 10 minutes. The supernatant was removed and retained. 500μL of the supernatant was diluted to 3000μL with 2500μL PBS buffer and then added to a cuvette. The absorbance of the diluted solution at 220nm was measured in a UV spectrophotometer. The results were as follows: Figure 5 (a) shown.

[0073] 3. Experimental results:

[0074] Generally, when the content of Asp6 in the dispersion is higher, the corresponding absorbance at 220nm should be higher. By comparing the absorbance at 220nm of four groups of PBS dispersions of ZnO-Asp6 with different concentrations after mixing with hydroxyapatite dispersions for 24 hours, it can be found that: in the experimental group of the present invention, with the increase of the initial polypeptide concentration, after centrifugation for 24 hours after mixing with the hydroxyapatite dispersion, the absorbance of the supernatant of each group showed an opposite trend, that is, the group with a higher initial polypeptide concentration had a lower absorbance. This indicates that during the mixing process, the ZnO-Asp6 nanoparticles, due to the bone targeting ability of Asp6, pull the entire nanoparticles to combine with the hydroxyapatite nanoparticles (such as Figure 5 (b) shows that after centrifugation of the supernatant, Asp6, which has a certain solubility in water, is separated as a precipitate phase during the centrifugation process due to its combination with hydroxyapatite. The higher the concentration of the group containing ZnO-Asp6 nanoparticles, the more extensive the combination with hydroxyapatite occurs, resulting in a large amount of Asp6 being separated and the absorbance of the supernatant decreasing. These results confirm that the carboxyl group on Asp6 grafted on the ZnO nanoparticles combines with the calcium ions on the HA crystals, which has a strong anchoring effect on the calcium ions on the surface of hydroxyapatite.

[0075] (III) Antibacterial effect of ZnO-Asp6 on Staphylococcus aureus

[0076] 1. Experimental strains:

[0077] The test strain, Gram-positive bacteria Staphylococcus aureus (S. aureus, CMCC26003), was purchased from Shanghai Collection Biotechnology Center.

[0078] 2. Experimental methods:

[0079] In order to further verify the killing effect of ZnO-Asp6 on bacteria, the most common Gram-positive bacteria of osteomyelitis, Staphylococcus aureus, was selected for antibacterial experiments.

[0080] Bacterial culture medium: nutrient broth medium containing Staphylococcus aureus, the inoculation density of Staphylococcus aureus is 1×10 8 CFU / mL. The ingredients of nutrient broth are peptone 10g / L, beef extract powder 3g / L, and sodium chloride 5g / L. The specific preparation process is: weigh 1.8g of nutrient broth ingredients, add it to 100mL of deionized water, heat and boil to dissolve, and sterilize at 121℃ for 30min.

[0081] Solid culture medium: Nutrient agar medium. The ingredients of nutrient agar are 10g / L peptone, 3g / L beef extract powder, 5g / L sodium chloride, and 15g / L agar. The specific preparation process is: weigh 3.3g nutrient agar, add it to 100mL deionized water, heat and boil to dissolve, and sterilize at 121℃ for 30min.

[0082] The specific steps are as follows: 6 pieces of sterilized filter paper each Soak in 1 mL of dispersions of different concentrations (pure PBS buffer for the control group, 1 mg / mL Asp6 dispersion in PBS, 2 mg / mL ZnO-Asp6 (prepared in Example 1) dispersion in PBS, 4 mg / mL ZnO-Asp6 (prepared in Example 1) dispersion in PBS, 2 mg / mL ZnO dispersion in PBS, 4 mg / mL ZnO dispersion in PBS) for 1 h for use.

[0083] Bacterial culture medium: Take 100 μL of bacterial culture solution and add it dropwise to the sterilized solid culture medium (solid culture medium is in a non-caking state and the temperature is about 50-60°C), and pour it into a plate to prepare bacterial culture medium. After standing for 8 hours, use a dispenser or sterile tweezers to stick the above filter paper (set up two parallel experimental groups) tightly to the culture dish. The center of each paper piece is ≥24mm apart. The paper should not be moved after it is attached. Incubate at 37°C for 24 hours, observe and use Image-J to measure the diameter of the inhibition zone. The results are shown in Table 1 and Figure 6 shown.

[0084] Table 1. Measurement results of the diameter of the inhibition zone

[0085] Material concentration Diameter of inhibition zone (parallel experimental group 1) Diameter of inhibition zone (parallel experimental group 2) Pure PBS - 9.4mm 9.74mm Asp6 1mg / mL 11.35mm 6.86mm ZnO-Asp6 4mg / mL 17.29mm 12.43mm ZnO-Asp6 2mg / mL 16.79mm 12.55mm ZnO 4mg / mL 17.14mm 16.07mm ZnO 2mg / mL 16.98mm 12.69mm

[0086] 3. Experimental results:

[0087] from Figure 6 As can be seen from Table 1, a certain size of inhibition zone appeared in the culture dish where the filter paper was co-cultured with the material dispersion after being soaked. Among them, the reason why the filter paper co-cultured with PBS buffer and ASP6 dispersion showed a smaller inhibition zone may be that after the filter paper was soaked and placed on the culture dish, there was still a trace amount of liquid infiltration, which caused the local bacterial concentration to be diluted, showing a certain size of inhibition zone.

[0088] The filter paper pieces immersed in ZnO-Asp6 and ZnO dispersions showed more obvious inhibition zones with larger diameters. The diameter of the inhibition zone of the filter paper piece immersed in 4 mg / mL ZnO-Asp6 dispersion reached 17.29 mm, which was much higher than the inhibition zones of the control group pure PBS group and ASP6 group, and close to the inhibition zone size of 4 mg / mL ZnO dispersion. This indicates that the surface modification of ZnO nanoparticles in the present invention does not affect its ability to eliminate bacteria, and has a good antibacterial effect.

[0089] Those skilled in the art will appreciate that the embodiments herein are intended to help readers understand the principles of the present invention, and should be understood that the protection scope of the present invention is not limited to such specific statements and embodiments. Those skilled in the art can make various other specific variations and combinations that do not deviate from the essence of the present invention based on the technical revelations disclosed by the present invention, and these variations and combinations are still within the protection scope of the present invention.

Claims

1. A bone-targeted, highly effective antibacterial zinc oxide nanoparticle, characterized in that: The invention comprises zinc oxide nanoparticles with active sites and bone targeting materials grafted onto the surface of the zinc oxide nanoparticles via the active sites.

2. The bone-targeted, highly effective antibacterial zinc oxide nanoparticles according to claim 1, characterized in that: The active site is an amino group; the bone targeting material is one of aspartic acid oligopeptide and glutamic acid oligopeptide.

3. The bone-targeted, highly effective antibacterial zinc oxide nanoparticles according to claim 2, characterized in that: The bone targeting material is aspartic acid hexapeptide.

4. A method for preparing bone-targeted, highly effective antibacterial zinc oxide nanoparticles, characterized in that: The following steps are involved: (1) using a silane coupling agent to perform surface amino modification on zinc oxide nanoparticles to obtain surface-modified zinc oxide nanoparticles; (2) Preparation of bone-targeted zinc oxide nanoparticles, specifically: The surface-modified zinc oxide nanoparticles are added to a bone-targeting material buffer with a pH of 5-5.5, and the pH of the resulting reaction system is adjusted to 5.5-6.5, followed by stirring for 4-5 hours, and then filtered, washed, and dried to obtain bone-targeting high-efficiency antibacterial zinc oxide nanoparticles; the mass ratio of the surface-modified zinc oxide nanoparticles to the bone-targeting material is 10:

1.

5. The method for preparing bone-targeted high-efficiency antibacterial zinc oxide nanoparticles according to claim 4, characterized in that: Step (1) comprises the following sub-steps: (11) adding a silane coupling agent to a uniformly dispersed zinc oxide nanoparticle dispersion and subjecting the dispersion to ultrasonic treatment for 20-40 minutes; the silane coupling agent is 20%-22% of the mass of the zinc oxide nanoparticles; and the silane coupling agent is γ-aminopropyltriethoxysilane or γ-methacryloxypropyltrimethoxysilane. (12) The dispersion after ultrasonic treatment is centrifuged multiple times, washed and dried to obtain surface-modified zinc oxide nanoparticles.

6. The method for preparing bone-targeted high-efficiency antibacterial zinc oxide nanoparticles according to claim 5, characterized in that: In step (11), zinc oxide nanopowder is added into anhydrous ethanol and dispersed evenly by ultrasonication to obtain a zinc oxide nanoparticle dispersion with a concentration of 20 mg / mL.

7. The method for preparing bone-targeted high-efficiency antibacterial zinc oxide nanoparticles according to claim 4, characterized in that: In step (2), the bone targeting material is dissolved in the first buffer to obtain a bone targeting material buffer with a concentration of 0.5 g / L, and the pH value of the bone targeting material buffer is adjusted to 5-5.5 by acid.

8. The method for preparing bone-targeted high-efficiency antibacterial zinc oxide nanoparticles according to claim 7, characterized in that: The first buffer is a MES buffer containing EDC and NHS; the mass ratio of EDC to NHS is 1:1; the volume ratio of the total mass of EDC and NHS to the MES buffer is 10-20 mg:1 mL.

9. The method for preparing bone-targeted high-efficiency antibacterial zinc oxide nanoparticles according to claim 4, characterized in that: The surface-modified zinc oxide nanoparticles are added to a bone-targeting material buffer, and a second buffer is used to adjust the pH value of the resulting reaction system to 5.5-6.5; the second buffer is a PBS buffer having a pH range of 7.2-7.

4.

10. Use of the bone-targeted, highly effective antibacterial zinc oxide nanoparticles according to any one of claims 1 to 3 in the preparation of drugs for treating bone tissue.

Citation Information

Patent Citations

  • Drug carrier with bone targeting as well as preparation method and application thereof

    CN110755638A

  • Antibacterial disinfection nanofiber medical dressing and preparation method thereof

    CN112972750A

  • Amino acid modified nanoparticles, preparation method and application thereof, and anti-fouling ultrafiltering film

    CN113831761A

  • L-cysteine grafted nano-zinc oxide water-based antibacterial colloid and preparation method thereof

    CN113892491A

  • Acidic oligopeptide modified bone targeting liposome and preparation method thereof

    CN115212317A

Cited By

  • Modified zinc oxide-based bone implantation scaffold material as well as forming method and preparation method thereof

    CN119499449A

  • Nanoparticle composition and application thereof

    CN120361294A